Germ Cell Tumors

P2, N=1376, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Jan 2027

The patient subsequently received 3 cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. This case highlights the importance of diagnostic adaptability, multidisciplinary care, and long-term follow-up in achieving successful outcomes for rare thoracic malignancies. Broader lessons include the value of pragmatic decision-making, judicious use of limited diagnostic tools, and structured follow-up strategies that can guide clinicians facing similar challenges in resource-limited environments.

Conclusion Combining classical tumor markers with simple hematological indices offers an expanded perspective on the tumor biology of testicular cancer. NLR and MPV/PLT may serve as complementary markers for tumor aggressiveness and systemic inflammatory response, potentially improving risk stratification and follow-up strategies.

The inguinal region of young males appears to be one of the favored sites for these tumors. Furthermore, NGS-based algorithms may fail to accurately classify such tumors.

We successfully established a TYST PDX model that retains tissue structure and protein expression signature of the patient's tumor tissue. Furthermore, this PDX model demonstrates high sensitivity to standard JEB chemotherapy and represents a valuable resource for translational research in pediatric germ cell tumors.

Primary hepatic EST is an infrequent but important differential diagnosis of HCC, particularly in young women without cirrhosis who present with markedly elevated AFP levels. Early biopsy confirmation and multidisciplinary management are essential, as this chemosensitive tumor may achieve long-term survival with timely systemic treatment.

P2, N=2, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2030 --> Dec 2025

Testicular/paratesticular updates address diagnostic criteria for mesothelium-derived lesions of the tunica vaginalis, recommended immunohistochemical panels for testicular sex cord-stromal tumors, and recommended nomenclature, specifically the use of "embryonic-type neuroectodermal tumor" rather than primitive neuroectodermal tumor (PNET) in the context of somatic transformation of testicular germ cell tumors. For penile squamous cell carcinoma, the summary emphasizes prognostic biomarkers, notably TP53 alterations and high risk HPV status, and nuances pertaining to pathologic staging.

In vivo dissection of the RNF126-MIDN axis shows that it governs EGR1 abundance and, consequently, the tumor-suppressor proteins PTEN and p53, thereby restraining the progression of testicular germ-cell tumors (TGCTs). Our findings reveal an unappreciated layer of MIDN regulation and identify the RNF126-MIDN ubiquitination cascade as a potential therapeutic vulnerability in TGCTs and related malignancies.

P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Jan 2027

These results demonstrate that F-9 cancer cells are significantly more sensitive to SELENOV than normal fibroblasts, with 50 µg/mL sufficient to trigger mitochondrial dysfunction, oxidative stress, and apoptosis. The findings highlight SELENOV's potential as a targeted anticancer agent, particularly for germ cell tumors.